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Abstract: The introduction of 5-HT3 receptor antagonist has revolutionized the prevention 
and treatment of nausea and vomiting in preschool aged children. These distressing symptoms, 
arising from multiple etiologies such as anesthesia, chemotherapy, and viral infection, are a 
major concern of patients and their families. Clinical research has demonstrated the antiemetic 
effectiveness of ondansetron in children. Although most of these studies focus primarily on 
preventing vomiting across the pediatric age group, they provide strong evidence for the use of 
ondansetron in preschool age children. For children at high risk, pediatric practice guidelines 
recommend ondansetron in conjunction with other antiemetics to achieve complete control of 
symptoms. 
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Introduction
Nausea and vomiting are frequently experienced in infancy and preschool age childhood 
(Iacono et al 2005). These distressing symptoms are associated with common childhood 
occurrences such as car travel and gastroenteritis as well as postoperative recovery 
and cancer-related interventions. Once considered an inconvenient but unavoidable 
outcome of anesthesia, surgery, chemotherapy and radiation, nausea and vomiting are 
now recognized as the number one concern of patients and their families (Eberhart 
et al 2002; Wisselo et al 2004; Lee 2005). Recent investigations have revealed that 
distress, discomfort, and disruption associated with nausea and vomiting are signiﬁ  -
cant even in the youngest of patients (Khalil et al 2005; Holdsworth 2006). Increased 
awareness, availability of 5-hydroxytryptamine (5-HT3) receptor antagonists, and 
combined anti-emetic strategies should decrease the incidence of nausea and vomiting 
in this overlooked age group.
The 5-HT3 receptor antagonist ondansetron, ﬁ  rst heralded by Lancet in 1987, was 
rapidly recognized as having broad applicability with signiﬁ  cant beneﬁ  ts (Anonymous 
1987). Initially studied in patients receiving cis-platinum, ondansetron was soon shown 
to be effective in preventing radiation- and chemotherapy-induced nausea and vomiting 
(Green et al 1989). By the early 1990s, it was documented that ondansetron decreased 
postoperative nausea and vomiting (PONV) in adults and children (Leeser and Lip 
1991; Litman et al 1994). In placebo-controlled and comparative studies of patients 
undergoing various oncologic therapies and surgical procedures, ondansetron had 
consistently performed in the prevention and treatment of vomiting. Unlike traditional 
antiemetics, ondansetron was not associated with pronounced adverse reactions such 
as electrocardiograph abnormalities, somnolence, dysphoria, dystonia, and confusion. 
Due to its favorable therapeutic index, ondansetron has become the most frequently 
prescribed antiemetic. For young children and other patients who cannot swallow pills, Therapeutics and Clinical Risk Management 2007:3(2) 334
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ondansetron is also available in dissolving tablets and oral 
liquid formulations (Dupuis and Nathan 2003).
Etiology
Nausea and vomiting arises from multiple etiologies. Each 
involves a complex series of humoral and neurological 
interactions resulting in the stimulation of the vomiting cen-
ter, a nucleus of cells in the medulla (Andrews and Hawthorn 
1988). Neurotransmitters involved in this process include 
dopamine, acetylcholine, histamine, endorphins, serotonin, 
and neurokinin (NK1) (Pisters and Kris 1998). Receptors for 
these neurotransmitters are common in the vomiting center, 
chemoreceptor trigger zones (CTZ), and gastrointestinal (GI) 
tract. The vomiting center receives input from at least four 
sources: the CTZ, GI tract, vestibular apparatus, and cerebral 
cortex. The CTZ, which lie in the brain stem beneath the 
fourth ventricle, sense chemical abnormalities in the body 
and indirectly receive input from the vagus nerves. Distention 
and inﬂ  ammation of the GI tract and other internal organs 
cause the release of emetogenic substances and stimulates 
the CTZ via the vagus. Vestibular apparatus plays a role in 
motion sickness while the cerebral cortex is instrumental in 
olfactory, emotional, and anticipatory nausea and vomiting. 
It is postulated that ondansetron and other 5-HT3 receptor 
antagonists exerts its antiemetic action both peripherally 
(vagus and sympathetic nerves) and centrally (CTZ and 
vomiting center) by blocking stimulation of serotonin recep-
tors (Pisters and Kris 1998).
Postoperative nausea and vomiting
PONV, which is deﬁ  ned as early (0–6 hours) and delayed 
(6–48 hours) has been extensively studied in children due 
to its frequency, predictability, and economic impact. It is 
postulated that the surgical and anesthesia-related etiology 
of PONV is multifactorial, arising from direct stimulation 
of the CTZ by anesthetic agents (ie, nitrous oxide, opioids, 
anticholinesterases, and volatile gases) indirect stimulation 
from vagal transmission secondary to surgical manipulation 
(Watcha and White 1992). Over 25 randomized control trials 
of ondansetron prophylaxis have been performed in infants 
and preschool aged children. In pediatric patients, PONV is 
the leading cause of delayed discharge and emergency read-
mission (Patel and Hannallah 1988; Gold et al 1989). These 
patients are 50%–75% more likely to develop PONV than 
their adult counter parts with an incidence of 34%–50% in 
school age children and 20% in preschool children (Cohen 
et al 1990). The highest incidence of PONV is associated 
with eye muscle surgery, tonsillectomy, adenoidectomy, 
orchidopexy, and hernia repair reported high as 88%, 70%, 
50%, and 40%, respectively (Lerman 1992; Watcha and 
White 1992). Recent studies have demonstrated that the 
occurrence of PONV in 1- and 2-year-olds is higher than 
previously documented (Khalil et al 2005). Risk factors for 
PONV in children are summarized in Table 1. Over the last 
three decades numerous antiemetic medications have been 
studied, including droperidol, metoclopramide, dimenhy-
drinate, promethazine, prochlorperazine, scopolamine, and 
corticosteroids but the greatest success has been documented 
with 5-HT3 receptor antagonists, in general, and ondansetron, 
in particular. 
Most pediatric PONV clinical trials have focused on 
early PONV, grouped preschool age children with school 
aged children, and reported emesis, not nausea, as their 
determinant factor. These data do not allow for easy analysis 
of antiemetic response to ondansetron in younger children 
and antinausea response in children overall. Other study 
limitations include a focus on prevention as opposed to 
treatment, high risk procedures such as strabismus repair and 
adenotonsillectomy, and combined therapy evaluations. For 
ease of comparison, results of these studies are discussed in 
this chapter as the number needed to treat (NNT) within a 
conﬁ  dence intervals of 95% (CI 95%). NNT is the number 
of subjects required to be treated to result in one less patient 
having symptoms compared with those patients who re-
ceived placebo. The smaller the NTT, the more effective is 
the medication. If not otherwise noted, NNT is reported for 
placebo-controlled studies. 
Meta-analyses of studies examining PONV prophylaxis 
with ondansetron, 50–100 µg/kg intravenously, found the 
NNT to be 3 (CI 95% 2–5) for early PONV (Tramer et al 
1997). In comparison, meta-analyses of early PONV prophy-
lactic dexamethasone (following tonsillectomy), droperidol, 
and metoclopramide found the NNT to be approximately 
4 (CI 95% 2–6), 5 (CI 95% 3–7), and 8 (CI 95% 5–28), 
respectively (Steward et al 2002; Henzi et al 1999, 2000). 
Table 1 Risk factors for postoperative nausea and vomiting in 
children
Surgery – type   Use of volatile anesthetics
Surgery – duration  Use of nitrous oxide
History of PONV  Use of opioids
History of motion sickness  Use of reversal agents
Adapted from Gan et al (2003).
Abbreviations: PONV, postoperative nausea and vomiting.Therapeutics and Clinical Risk Management 2007:3(2) 335
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In children, other available 5-HT3 receptor antagonists have 
similar treatment proﬁ  les compared with ondansetron (Gan 
2005).
Adverse drug reactions with ondansetron use are re-
ported as being equal to or less than that reported in control 
(placebo) groups (Culy et al 2001). Less than 1% of children 
complain of headache or dizziness. Other reported adverse 
responses, which are rare but serious, include electrocardi-
ography alteration involving sodium channels changes, cen-
tral nervous changes such as dyskinesias, and elevated liver 
enzymes (Goodin and Cunningham 2002; Kovac 2002). In 
contrast, side-effects reported with metoclopramide such 
as headaches, high levels of sedation, and extrapyramidal 
symptoms occurred with statistically signiﬁ  cant greater 
frequency (Domino et al 1999). Droperidol proﬁ  le is less 
favorable secondary to more pronounced side-effects such 
as somnolence and a theoretical increased risk of cardiac 
arrhythmia in children.
Chemotherapy-induced nausea 
and vomiting
In patients of all ages, chemotherapy-induced nausea and 
vomiting (CINV) and radiation-induced nausea and vom-
iting (RINV) are sited as the most common fear and the 
leading cause of poor compliance (Coates et al 1983). The 
percentage of patients experiencing vomiting with speciﬁ  c 
chemotherapy agents ranges from greater than 90% with 
cisplatin (>50 mg/m2) to less than 10% with vincristine 
(Schnell 2003). High, moderate, and low risk emetogenic 
agents are presented in Table 2. 
CINV is classiﬁ  ed as acute, delayed, and anticipatory 
with severity directly related to emetogenic potential of anti-
oncologic therapy and efﬁ  cacy of prevention and treatment 
(Antonarakis and Hain 2005). Acute CINV, by deﬁ  nition, 
occurs within 24 hours after a chemotherapy dose. With 
modern antiemetic prophylaxis 76%–86% of children receiv-
ing a variety of emetogenic chemotherapy agents are emesis 
free (Foot and Hayes 1994; Kusnierczyk et al 2002). Delayed 
CINV occurs 24 hours or more after a chemotherapy dose 
and may persist for 5–7 days. The incidence, patterns, and 
risk factors in children are poorly understood but delayed 
CINV is more commonly associated with the use of cisplatin, 
carboplatin, and/or cyclophosphamide as well as vomiting 
during the acute phase (Dupuis and Nathan 2003). Anticipa-
tory CINV occurs prior to the administration of chemotherapy 
and, like delayed CINV, appears linked to poor emetic control 
during previous chemotherapy treatments. In children, pre-
school and school age, the incidence of anticipatory CINV 
has been reported to range from 15% to 54%, depending on 
research methods and antiemetic prophylaxis history (Foot 
and Hayes 1994; Tyc et al 1997) These data reinforce the 
importance of achieving excellent emetic control in children 
receiving chemotherapy.
The advent of 5-HT3 receptor antagonists has markedly 
improved patient lives. The different available agents have 
shown uniform advantages over older antiemetics. Of these 
medications, ondansetron has been extensively studied for 
prophylaxis against and treatment of CINV. Most papers 
that examine prophylactic ondansetron use in children 
examine early CINV in clinical reports. There are fewer 
than 10 randomized, controlled studies available in this age 
group and only 1 with a placebo-treated control group. The 
remainder of the studies reviewed compare ondansetron with 
phenothiazine derivatives. Because chemotherapy protocols 
(medications, dosing, and cycles) and antiemetic regimens 
(dosing, route, and frequency) vary with different cancers and 
Table 2 Emetogenic potential of chemotherapy agents risk and (%)
High risk (>90 %)  Carmustine >250 mg/m2 Cisplatin >50 mg/m2  Lomustine >60 mg/m2 Mechlorethamine Streptozocin
  Cyclophosphamide >1.5 g/m2 Dacarbazine >500 mg/m2 
High risk (60–90%)  Carmustine <250 mg/m2 Cisplatin   Dactinomycin >1.5 mg/m2 Doxorubicin
 <50  mg/m2 Cyclophosphamide 0.75–1.5 g/m2   >60 mg/m2 Mitoxantrone >15 mg/m2
  Dacarbazine <500 mg/m2  Methotrexate >1000 mg/m2
High risk (30–60%)  Cyclophosphamide <0.75 g/m2  Epirubicin ≤90 mg/m2 Idarubicin Ifosfamide
  Dactinomycin ≤1.5 mg/m2 Daunorubicin  Methotrexate 0.25–1 g/m2
  Doxorubicin 20–60 mg/m2   
Moderate risk (10–30%)  Asparaginase Cytarabine <1 g/m2  Etoposide Fluorouracil <1 g/m2 Methotrexate
  Doxorubicin <20 mg/m2 Docetaxel 50–250  mg/m2 Mitomycin
Low risk (<10%)  Bleomycin Busulfan Chlorambucil Fludarabine  Methotrexate <50 mg/m2  Thioguanine
   Vinblastine  Vincristine
Adapted from Hesketh et al (1997).Therapeutics and Clinical Risk Management 2007:3(2) 336
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treatment centers, comparison among studies is problematic. 
In addition, placebo-controlled trials performed solely in 
infants and preschool aged children are unavailable. 
Keeping these limitations in mind, some data can be 
generalized for the use of 5-HT3 receptor antagonists in pre-
venting and treating CINV. Children 18 months to 15 years of 
age receiving highly emetogenic agents have been described 
in a systematic review as having anywhere from 25% to 
100% complete or major control of acute vomiting with 
ondansetron therapy (Antonarakis et al 2004). Holdsworth 
et al (1995) compared ondansetron treated and non-treated 
pediatric patients receiving carmustine, etoposide/cytarabine 
or cyclophosphamide and determined the NNT as 3 (CI 95% 
2–7). In a similar age group receiving high dose (4.5 mg/kg) 
ondansetron, Parker and colleagues (2001) found the NNT to 
prevent CINV from intrathecal methotrexate to be 2. 
In comparative trials with traditional antiemetics, ondan-
setron has been shown to have greater efﬁ  cacy. In one study, 
children 18 months to 15 years of age receiving an intensiﬁ  ca-
tion chemotherapy regimen for acute lymphocytic leukemia 
were randomized to receive either ondansetron (3–5 mg/m2) 
or metoclopramide plus dexamethasone and procyclidine. 
Complete or major control of vomiting was achieved in 93% 
and 33% of children in each group, respectively (Dick et al 
1995). In a similar study of children receiving emetogenic 
chemotherapy, Koseoglu and colleagues (1998) also demon-
strated that ondansetron produced superior relief of symptoms. 
In randomized, controlled studies of 5-HT3 receptor antago-
nists, ondansetron appeared to be equivalent to granisetron 
but more effective than tropisetron (Stiakaki et al 1999; Jaing 
et al 2004). Granisetron has a longer duration of action, which 
offers advantages in terms of dosing schedules. 
Studies of radiation-induced nausea vomiting in young 
children are limited. However, in combined studies with older 
children superior control of emesis, compared with pheno-
thiazine derivatives, was demonstrated with ondansetron 
alone (Jurgens and McQuade 1992; Tramer et al 1998) and 
in combination with dexamethasone (Roberts and Priestman 
1993; Kusnierczyk et al 2002). 
Gastroenteritis
Gastroenteritis remains a major cause of morbidity and hos-
pitalization in industrialized nations. In the United States, 
children younger than 5 years have 1 to 2 infections per year, 
resulting in 1.5 million medical consultations, and 200,000 
hospitalizations (Pashar et al 1998). Hospitalizations are due 
to diarrhea and dehydration. Control of vomiting, in order to 
establish oral rehydration, can be important in counteracting 
these problems. However, in 1996 the American Academy of 
Pediatrics reported a consensus opinion that antiemetic medi-
cations were not indicated in children with gastroenteritis. 
They advised caution in prescribing these agents secondary 
to risk for adverse side-effects (Anonymous 1996).
Randomized, placebo-controlled trials have since demon-
strated the efﬁ  cacy and safety of ondansetron in the treatment 
of established nausea and vomiting associated with gastroen-
teritis. Reeves et al (2002) studied 107 children 3 months to 
22 years of age (mean 5.5 years) and determined a NNT of 5.3 
(NA) for cessation of vomiting and 6.25 to prevent hospital 
admission. In children 6 months to 12 years of age, Ramsook 
et al (2002) demonstrated a NNT of 4.5 (CI 95% 1.2–5.4) for 
cessation of vomiting and of 8.3 to avoid administration of 
intravenous ﬂ  uids. Although oral rehydration therapy remains 
the primary and essential focus, the Center of Disease Control 
and the American Academy of Pediatrics now recognize that 
ondansetron 100–150 µg/kg “can be effective in decreasing 
vomiting and limiting hospital admission” in gastroenteritis 
(Anonymous 2004; King et al 2003).
Other causes of nausea 
and vomiting
The incidence of opioid induced nausea and vomiting has 
been reported to range from 20% to 40% depending on 
medication and patient population (Campora et al 1991; Zun 
et al 2002). High dose ondansetron used in (8–16 mg orally 
or 1.5 mg/kg intravenously) has shown limited effectiveness 
in patients receiving neuraxial morphine, a mixture of oral 
opioid preparations, and morphine patient-controlled anal-
gesia (PCA) with NNT of 3 (CI 95% 2–11), 4.3 (NA), and 3 
(CI 95% 2–5), respectively (Alexander et al 1995; Sussman 
et al 1999; Tzeng et al 2003). In children, 2–10 years of age, 
receiving oral transmucosal fentanyl citrate with a PONV 
of 45%, Binstock and colleagues (2004) were not able to 
demonstrate a signiﬁ  cant antiemetic effect with ondansetron. 
Similarly, Munro et al (2002) found no response in children, 
5–13 years of age, on morphine PCA.
Motion sickness is a common disorder related to confu-
sion between sensory and cognitive functions. Motion sick-
ness affects greater than 50% of children traveling in cars and 
planes. Symptoms tend to be most severe between 4 and 10 
years of age (Setness and Van Beusekom 2004). Although 
there are no published studies examining the use of ondanse-
tron for this disorder, motion sickness is commonly used as a 
predictor of PONV and CINV. A meta-analysis performed by Therapeutics and Clinical Risk Management 2007:3(2) 337
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Figueredo and Canosa (1999) detected a NNT of 3.4 (CI 95% 
2.1–5.4) and 6.4 (NA) for prophylactic ondansetron (4 mil-
ligrams, intravenously) to prevent PONV in adult patients 
with a positive and negative history of motion sickness. This 
ﬁ  nding suggests a role for ondansetron in preventing and/or 
reducing the symptoms of motion sickness. 
Combination therapy
Contemporary practice guidelines, based on extensive review 
of randomized control studies, for children at high risk for 
PONV and CINV recommend ondansetron in conjunction 
with other antiemetics (Culy et al 2001; Dupuis and Nathan 
2003; Gan et al 2003). Combination therapy is superior 
to single-drug prophylaxis for PONV and CINV (Alvarez 
et al 1995; Habib et al 2001). Efﬁ  cacy can be optimized by 
taking advantage of the different medications’ mechanisms 
of action. In a particular, ondansetron in combination with 
corticosteroids has been shown to be the optimal treatment 
for PONV associated with tonsillectomies and highly emeto-
genic chemotherapy agents. Dosing regimes still need to be 
established but current literature contains the following rec-
ommendations for PONV: 150–500 µg (maximum of 10–12 
mg) for dexamethasone, 50–75 µg/kg (maximum of 1.25 mg) 
for droperidol, 500 µg/kg for dimenhydrinate and 70 µg/kg 
for perphenazine (Gan et al 2003). The dose of ondansetron 
doses (100–150 µg/kg) may be reduced when used in com-
bination with another antiemetic (Tramer 2001). Triple com-
bination regiments are recommended for patients at high risk 
for PONV and CINV. Dosing for antiemetic prophylaxis for 
CINV include ondansetron 3–5 mg/m2 and dexamethasone 
8–16 mg/m2 (Curly et al 2001). Guidelines for prophylactic 
therapy for children at risk for nausea and vomiting, based 
on available data from randomized controlled studies and 
expert consensus, are summarized in Table 3.
Conclusions
Ondansetron has shown good efﬁ  cacy in the prevention 
and treatment of nausea and vomiting in young children 
with exposure to emetogenic agents, which include anes-
thetic agents, oncologic therapeutics, or viral infections. In 
children undergoing surgery associated with a high risk of 
PONV, ondansetron demonstrated superior prophylactic 
antiemetic efﬁ  cacy compared with placebo, droperidol, and 
metoclopramide. It has been demonstrated that ondansetron 
is relatively free of adverse events. When combined with 
dexamethasone, ondansetron has been shown to establish 
almost complete control of emesis. Depending on risk factors 
for nausea and vomiting, ondansetron, alone or in combina-
tion, is the treatment of choice for young children undergoing 
surgery and chemotherapy.
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